ProPhase Labs, Inc. (PRPH): Price and Financial Metrics


ProPhase Labs, Inc. (PRPH): $8.08

-0.13 (-1.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PRPH POWR Grades

  • Value is the dimension where PRPH ranks best; there it ranks ahead of 92.97% of US stocks.
  • PRPH's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • PRPH ranks lowest in Momentum; there it ranks in the 13th percentile.

PRPH Stock Summary

  • PRPH's current price/earnings ratio is 4.24, which is higher than only 7.87% of US stocks with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, PROPHASE LABS INC is reporting a growth rate of -1,035.63%; that's higher than only 1.72% of US stocks.
  • As for revenue growth, note that PRPH's revenue has grown 273.85% over the past 12 months; that beats the revenue growth of 96.68% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to PROPHASE LABS INC, a group of peers worth examining would be ASRT, PIPR, WWE, BGCP, and BOXL.
  • Visit PRPH's SEC page to see the company's official filings. To visit the company's web site, go to www.prophaselabs.com.

PRPH Valuation Summary

  • PRPH's EV/EBIT ratio is 3.5; this is 64.65% lower than that of the median Healthcare stock.
  • PRPH's price/sales ratio has moved down 1.5 over the prior 243 months.

Below are key valuation metrics over time for PRPH.

Stock Date P/S P/B P/E EV/EBIT
PRPH 2023-01-20 1.0 2.1 4.6 3.5
PRPH 2023-01-19 1.0 2.1 4.5 3.4
PRPH 2023-01-18 1.0 2.1 4.6 3.5
PRPH 2023-01-17 1.1 2.3 4.9 3.7
PRPH 2023-01-13 1.0 2.2 4.8 3.7
PRPH 2023-01-12 1.0 2.2 4.9 3.7

PRPH Growth Metrics

    The 4 year cash and equivalents growth rate now stands at -98.37%.
  • Its 5 year cash and equivalents growth rate is now at -98.37%.
  • Its 3 year revenue growth rate is now at 824.74%.
PRPH's revenue has moved up $136,104,000 over the prior 33 months.

The table below shows PRPH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 145.98 23.093 31.497
2022-06-30 131.252 14.939 26.551
2022-03-31 111.302 14.56 17.71
2021-12-31 79.042 -13.619 6.273
2021-09-30 39.048 -15.74 -5.294
2021-06-30 33.416 -10.699 -1.724

PRPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PRPH has a Quality Grade of F, ranking ahead of 3.86% of graded US stocks.
  • PRPH's asset turnover comes in at 0.618 -- ranking 52nd of 680 Pharmaceutical Products stocks.
  • NBIX, CEMI, and ENDP are the stocks whose asset turnover ratios are most correlated with PRPH.

The table below shows PRPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.618 0.488 -0.022
2021-03-31 0.733 0.470 0.011
2020-12-31 0.738 0.317 -0.105
2020-09-30 0.839 0.299 -0.131
2020-06-30 0.876 0.309 -0.152
2020-03-31 0.680 0.266 -0.244

PRPH Price Target

For more insight on analysts targets of PRPH, see our PRPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.50 Average Broker Recommendation 1.75 (Moderate Buy)

PRPH Stock Price Chart Interactive Chart >

Price chart for PRPH

PRPH Price/Volume Stats

Current price $8.08 52-week high $15.25
Prev. close $8.21 52-week low $6.20
Day low $7.92 Volume 65,000
Day high $8.23 Avg. volume 54,311
50-day MA $9.83 Dividend yield N/A
200-day MA $10.39 Market Cap 131.53M

ProPhase Labs, Inc. (PRPH) Company Bio


ProPhase Labs, Inc. manufactures zinc gluconate glycine lozenges and homeopathic gum. The Company's products reduce the duration and severity of common cold symptoms. ProPhase also manufactures nutrition and weight management products.


PRPH Latest News Stream


Event/Time News Detail
Loading, please wait...

PRPH Latest Social Stream


Loading social stream, please wait...

View Full PRPH Social Stream

Latest PRPH News From Around the Web

Below are the latest news stories about PROPHASE LABS INC that investors may wish to consider to help them evaluate PRPH as an investment opportunity.

While insiders own 21% of ProPhase Labs, Inc. (NASDAQ:PRPH), individual investors are its largest shareholders with 60% ownership

If you want to know who really controls ProPhase Labs, Inc. ( NASDAQ:PRPH ), then you'll have to look at the makeup of...

Yahoo | January 19, 2023

ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test

GARDEN CITY, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it has completed its previously announced acquisition of the world-wide exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic screening test and related intellectual property assets from Stella Diagnostics, Inc. (“Stella”). The BE-Smart test is focused on the early detection of esophageal cance

Yahoo | January 5, 2023

ProPhase Labs''s Return On Capital Employed Overview

Pulled from Benzinga Pro data, ProPhase Labs (NASDAQ: PRPH ) posted Q3 earnings of $968 thousand, an increase from Q2 of 87.0%. Sales dropped to $24.20 million, a 16.82% decrease between quarters. ProPhase Labs earned $7.45 million, and sales totaled $29.09 million in Q2. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a … Full story available on Benzinga.com

Benzinga | December 20, 2022

ProPhase Labs Stock: Betting On The DNA Sequencing Market For Future Growth (NASDAQ:PRPH)

ProPhase Labs has strengthened its fundamentals through profitable COVID-19 testing. Read why I downgrade my initial stance to a Hold position for PRPH stock.

Seeking Alpha | December 20, 2022

ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test

GARDEN CITY, NY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. “ProPhase” (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics…

GlobeNewswire | December 19, 2022

Read More 'PRPH' Stories Here

PRPH Price Returns

1-mo -15.22%
3-mo -29.06%
6-mo -24.27%
1-year 11.91%
3-year 325.26%
5-year 239.50%
YTD -16.10%
2022 34.31%
2021 -21.90%
2020 365.99%
2019 -37.46%
2018 45.16%

Continue Researching PRPH

Here are a few links from around the web to help you further your research on ProPhase Labs Inc's stock as an investment opportunity:

ProPhase Labs Inc (PRPH) Stock Price | Nasdaq
ProPhase Labs Inc (PRPH) Stock Quote, History and News - Yahoo Finance
ProPhase Labs Inc (PRPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8121 seconds.